Cyproterone acetate and risk of meningioma: a nationwide cohort study

J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):222-223. doi: 10.1136/jnnp-2021-326138. Epub 2021 Jun 29.

Authors

Anders Pretzmann Mikkelsen^{1

2}, Iben Katinka Greiber^{2

3}, Nikolai Madrid Scheller^{4

5}, Malene Hilden^{4

6}, Øjvind Lidegaard^{4

2}

Affiliations

¹ Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark anders.mikkelsen@regionh.dk.
² Deptartment of Clinical Medicine, University of Copenhagen, Cobenhavn, Denmark.
³ Department of Obstetrics, Rigshospitalet, Copenhagen, Denmark.
⁴ Department of Gynaecology, Rigshospitalet, Copenhagen, Denmark.
⁵ Department of Surgery, Queen Ingrid's Hospital, Nuuk, Greenland.
⁶ Centre for Gender Identity, Rigshospitalet, Copenhagen, Denmark.

PMID: 34187864
DOI: 10.1136/jnnp-2021-326138

No abstract available

Keywords: epidemiology; medicine; pharmacology; tumours.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Androgen Antagonists / adverse effects*
Cohort Studies
Cyproterone Acetate / adverse effects*
Denmark
Female
Humans
Male
Meningeal Neoplasms / chemically induced*
Meningioma / chemically induced*
Prospective Studies

Substances

Androgen Antagonists
Cyproterone Acetate